CD8A and neoplasm: Therapeutic targeting of eEF2K by specific inhibitor or RNA interference results in reduced PD-L1 expression, enhanced CD8+ T cell-mediated tumor cell killing and synergistically boosts the effects of PD-1 blockade (figure 8J), thus making eEF2K an attractive target in designing antitumor therapies against melanoma.